Cognition Therapeutics Reports FY25 Results, Advancing Zervimesine for DLB Psychosis Treatment

Cognition Therapeutics reported year-end 2025 financial results, with cash, cash equivalents, and restricted cash equivalents at approximately $37.0 million. The company is advancing zervimesine clinical development in DLB psychosis, with a meeting with FDA Division of Psychiatry expected by mid-2026. Management will host a live webcast conference call to review financial results and provide an update on clinical development plans.